Joincare Pharmaceutical Group Industry Co.,Ltd. Stock price

Equities

600380

CNE000001816

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
10.9 CNY -0.91% Intraday chart for Joincare Pharmaceutical Group Industry Co.,Ltd. -7.08% -12.31%
Sales 2023 * 16.49B 2.28B Sales 2024 * 18.17B 2.51B Capitalization 20.2B 2.8B
Net income 2023 * 1.39B 192M Net income 2024 * 1.63B 226M EV / Sales 2023 * 1.23 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.11 x
P/E ratio 2023 *
14.8 x
P/E ratio 2024 *
12.6 x
Employees 14,116
Yield 2023 *
1.56%
Yield 2024 *
1.74%
Free-Float 47.88%
More Fundamentals * Assessed data
Dynamic Chart
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President MT
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment MT
Shandong Boan Biotechnology Co., Ltd. Enters into Agreement with Joincare Pharmaceutical Group Industry Co., Ltd CI
Joincare Pharmaceutical, Guangzhou Fermion Technology Get Nod to Trial Analgesic Drug MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical MT
Joincare Pharma’s 210 Drugs Included in China's Medical Insurance Catalog MT
Joincare Gets Nod to Trial Pain Relief Drug MT
Joincare Pharma Shortlisted For China’s Drug Procurement Program MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022. CI
Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback announced on December 15, 2022 has closed with 49,706,643 shares, representing 2.61% for CNY 599.91 million. CI
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Joincare Pharma Unit Gets Go Signal from China for Phase 3 Trial of Endometriosis Drug MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022. CI
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day-0.91%
1 week-7.08%
Current month-9.77%
1 month-9.02%
3 months-11.45%
6 months-11.81%
Current year-12.31%
More quotes
1 week
10.87
Extreme 10.87
11.57
1 month
10.87
Extreme 10.87
12.25
Current year
9.70
Extreme 9.7
12.90
1 year
9.70
Extreme 9.7
14.24
3 years
9.70
Extreme 9.7
17.60
5 years
7.51
Extreme 7.51
22.47
10 years
4.85
Extreme 4.85
30.02
More quotes
Managers TitleAgeSince
President 63 21-08-26
Director of Finance/CFO 53 12-08-27
Director/Board Member 38 -
Members of the board TitleAgeSince
Founder 62 92-12-17
Director/Board Member 55 12-08-27
Director of Finance/CFO 53 12-08-27
More insiders
Date Price Change Volume
24-03-27 10.9 -0.91% 7,899,900
24-03-26 11 -1.26% 13,611,520
24-03-25 11.14 -0.71% 7,485,154
24-03-22 11.22 -3.03% 16,968,590
24-03-21 11.57 -1.36% 7,604,379

End-of-day quote Shanghai S.E., March 26, 2024

More quotes
Joincare Pharmaceutical Group Industry Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals and healthcare products. The Company's products include chemical materials and intermediates, chemical agents, health products, traditional Chinese medicines, diagnostic reagents and equipment. The Company is also engaged in electricity business. The Company distributes its products within domestic market and to overseas markets.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.9 CNY
Average target price
14.81 CNY
Spread / Average Target
+35.87%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Joincare Pharmaceutical Group Industry Co.,Ltd. - Shanghai S.E.